Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Fly like an aegle dit is zeker een mooie prijs voor een mooi bedrijf als ARGx is, en het is naar mijn mening ook dik verdiend. AB van mij voor het plaatsen.
Argenx: The New Ablynx? (Ook vergelijking met GLPG )seekingalpha.com/article/4012637-arge... Summary Argenx seems to be a spin-off of Ablynx (a successful Belgian biotech company). However, today we explain the differences between the two. We also take a look at Argenx's pipeline and discuss why we're having high hopes for its products, especially for Gerilimzumab. Last but not least, we compare its valuation to its two Belgian peers and take a look at its burn rate and current cash position. Everyone who's looking for a high-potential biotech stock with a high reward/relatively high risk ratio, should look no further. We asked our blog followers a while ago which stock they wanted us to analyze. The answer was obvious: Argenx (OTC:ARGNF) (22% of votes) and Ericsson (NASDAQ:ERIC) (20% of votes). Today, we'll fulfill our promise considering Argenx. Argenx (founded in 2008 and went public in 2014) seems to be a direct spin-off of Ablynx (OTC:ABLYF). Not only is the CEO a former employee of Ablynx (Tim Van Hauwermeiren) but Argenx works - like Ablynx - with llamas to develop new medicines. Differences Llamas have two kinds of antibodies. Ablynx uses the nano-antibodies of llamas (which can be used for a broad spectrum of diseases) while Argenx uses the ordinary antibodies in order to target cancers and autoimmune diseases. In other words, Argenx focuses on two specific niches (cancer and auto-immune diseases). Huge market The antibodies that Argenx develops are also called therapeutic antibodies. These types of antibodies have numerous properties, which make them very suitable as medicinal products. They can generally bind better to the proposed target, they have fewer side effects, and can activate powerful killing mechanisms within the human body. Therapeutic antibodies have already been developed for the treatment of a large number of diseases such as cancer, inflammation, ophthalmology, infectious diseases, and cardiovascular and metabolic disorders. Important to know is that in 2013 five of the ten top-selling drugs were therapeutic antibodies. Sales of all therapeutic antibodies in 2013 exceeded 60 billion USD. How does it work Argenx adjusts ordinary antibodies from llamas (which very closely resembles human antibodies but are much more powerful) by using its Fc engineering technology platform. After fine-tuning the properties of the antibodies (expanding the half-time, making them better recognize the targets and giving them better abilities to kill the targeted cells) the antibodies are introduced into the body of the patient. These new antibodies will then strengthen and help the natural defenses of the human body in order to exterminate, disable or weaken the proposed illnesses. Promising pipeline Products: ARGX-109, ARGX-110, ARGX-111 and ARGX-113 are most important to Argenx. These have already begun their phase II studies (or are about to start them). During these studies, the appropriate doses of the products are determined by testing them on a larger group of healthy people. The potential drugs are also tested on a larger group of patients that are ill. Excellent Phase II results are therefore crucial for Argenx.
vervolg ARGX-113 ARGX-113 could be used against many autoimmune diseases. But the first autoimmune diseases that Argenx is going to test it on are Myasthenia Gravis (MG) and Immune Thrombocytopenia (ITP). MG is the name of a condition that leads to the failure or insufficient functioning of the muscles (range: 20 people per 100,000). ITP is a relatively rare blood disorder in which the blood does not clot well (range: 3 people per 100,000). The phase Ia study with single ascending doses and the phase Ib study in which Argenx uses multiple ascending doses of ARGX-113 were very positive and indicated that ARGX-113 was well tolerated by the human body and therefore is safe to use. We expect that the Phase II trials for ARGX-113 will also be successful due to strong proof-of-concept studies. ARGX-110 ARGX-110 is designed for the blocking of CD70. CD70 is a protein expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes do not express a lot of CD70. In understandable words: CD70 often occurs in blood cancers (lymphoma and leukemia), multiple solid tumors and auto-immune diseases, but rarely in healthy cells. ARGX-110 is supposed to have a triple function: It blocks the growth of tumor cells, it kills cancer cells and activates the immune system of the patient to attack the tumor. ARGX-110 is also sponsored by the Leukemia & Lymphoma Society for the Development of WM (Waldenstrom's macroglobulinemia), a rare lymphoma. A Phase I/II combination study of the potential combination of ARGX-110 with another drug (Romidepson) against CTCL (cutaneous T-cell lymphoma) is currently being launched and tested. Phase I trials were already positive. We are very positive about the phase II study of ARGX-110 and expect a favorable outcome here (also due to very strong proof-of-concept studies). ARGX-115 Earlier this year, Argenx managed to close a major alliance with pharma giant AbbVie (NYSE:ABBV) to develop ARGX-115 (cancer treatment). Argenx immediately received 40 million USD in cash and can - if it successfully continues its research - receive up to 645 million USD. Many considered this deal as a first major recognition of Argenx's technology. We believe this is wrong. ARGX-109 We believe that Argenx's received huge recognition for its technology in 2012 as Argenx managed to close a deal on Gerilimzumab (ARGX-109) with RuiYi (currently Bird Rock Bio). The terms of the deal were never shared with investors (as Argenx wasn't a public company at the time), but Bird Rock Bio has a lot of confidence in ARGX-109 as a potential alternative treatment for rheumatoid arthritis (a disease that's affecting > 20 million people, and generates more than 35 billion USD sales). More so, Bird Rock Bio hopes to put Gerilimzumab in the market as a disruptive medicine (as it would require fewer treatments and is much cheaper than regular RA drugs). Due to the global scale of rheumatoid arthritis, combined with an aggressive pricing plan, we believe that ARGX-109's revenue potential is huge. The first tests with Gerilimzumab on healthy humans were completed earlier this year. The results were very positive and Bird Rock Bio plans on doing some vital pivotal phase II studies soon. Partnerships Next to these partnerships, Argenx also closed partnerships with Shire (NASDAQ:SHPG) (for the discovery of antibodies that treat rare diseases) and Leo Pharma (to find better treatments for skin conditions). As a young biotech company, the total amount that Argenx could receive after reaching crucial milestones is already more than 2 billion EUR. Cash burn Argenx's cash position stood at ~109 million EUR at the end of H1 2016. This piggy bank will enable Argenx to continue its developments for at least a few years. Currently, Argenx burns around 15 million EUR per year (although we expect its cash burn to accelerate due to the commencement of several phase II studies). Valuation Galapagos Argenx Ablynx Market value 2.66 billion EUR 296 million EUR 655 million EUR Enterprise value 1.70 billion EUR 187 million EUR 460 million EUR Clinical pipeline 8 products 4 products 9 products Phase III 1x Filgotinib 0x 1x Caplacizumab Phase II 4x 2x 5x Phase I 3x 2x 3x When comparing Argenx to its two Belgian peers: Ablynx and Galapagos (NASDAQ:GLPG), one quickly sees that Argenx has the smallest pipeline and therefore also receives a lower valuation from investors. We believe however, that Argenx should probably be worth half the market size of Ablynx, which would lead to a 327 million EUR market cap at current prices. By comparing the three companies, one might also argue that the upside potential for Argenx is much higher than for the other two companies and is therefore a better buy.
vervolg Conclusion We believe Argenx is a really interesting biotech company. If everything goes well, then ARGX-110 and ARGX-113 could soon present promising phase II results. Next to ARGX-110 and ARGX-113, we also think that Gerilimzumab or ARGX-109 (under development at Bird Rock Bio) might turn out to be a major positive surprise for investors. And last but not least Argenx will soon look (and probably find) a partner for ARGX-111. All of the above are powerful positive price triggers, which might push Argenx share price towards 20 EUR or higher. But as with any biotech company, the positive thesis is only valid if things go well. When comparing Argenx to its larger and more advanced peers, we believe Argenx is almost "priced to perfection" (taking into account the uncertainties and limited pipeline). However, a first position is still appropriate for investors who think long term and have a very differentiated portfolio. Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in ARGNF over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
Bioscience bedankt voor het plaatsen, ik had het gemist op S.A
had seekingalpha analyse ook gezien maar vergelijking met Ablynx en de antibodies die argenix ontwikkelen zijn toch echt iets anders maar goed daarom ben ik hierin geschoold en doet niet veel af aan de analyse.
Misschien wel weer instappen..
Heb ik iets gemist ? De koers ligt al sinds 10u op 13,90 ! Wat is er aan de hand ?
JoHo De handel is dun, en ook het publiek is dun gezaaid. Dit terwijl de Q3 cijfers best mooi zijn en veel vertrouwen geven naar de toekomst. Met een cash van 103mln De bevestiging van de veiligheid en effectiviteit van de diverse onderzoeken en het nog dit jaar starten van diverse fases van onderzoek.
De nieuwe corporate presentation van november 2016 staat op de websitewww.argenx.com/en-GB/content/financia... en dan doorklikken naar downloads en corporate prensentation
@Terra2000: dank voor de info !
Behoorlijk groot volume? Ik zie ruim 50k stukken, klopt dat? Met een dagverlies van 2 1/2%. Fors.
@de speurneus: Klopt, zie ik ook. Omzet is wel groter geweest eerder in sept en juni. Daarna ging het omhoog.
De CEO heeft een deel van z'n aandelen verkocht. Goed bezig.
Aantal targets eindigen fase 2 in Q4 van 2016. ARGX-110; T-Cell Lmphoma en Acute Myeloid leukemie. ARGX-113; Myasthenia Gravis en Immune Thrombocytopenia(die staat op voor Q1 2017. Resultaten van Fase 2 moeten dan toch ieder moment bekend worden gemaakt? Of is begin 2017 realistischer?
De corporate presentation van november zou antwoord moeten geven op je vraag. blz. 5: progress to clinical PoC ARGX-113 (Ph2 2017) ARGX-110 (Ph2 2017) ARG 111 fase 1 is afgerond, fase 2 staat niet aangegeven, wacht denk ik op partner. blz.6: ARG 113: MG start fase 2 4Q '16 IT start fase 2 Q1 '17 ARG 110: T-cl start fase 2 Q4 '16 AML start fase 2 Q4 '16 van ARG 110 Ik dacht zelf dat er dit jaar alleen nog gegevens van de expansion cohort van ARG 110 bekend zou moeten worden gemaakt.
Ja dat Tim weer heeft verkocht, hou ik ook niet van. Maar goed van winst nemen is niemand armer geworden en hij heeft er nog zat over. Overigens hebben zijn co-founders als Hans de Haard die echt weet waar het overgaat als CSO helemaal niks verkocht.
Helemaal correct Fly . Ik zie ook liever kopers dan verkopers . Het zegt echter helemaal niets . Deze mensen hebben ook wel eens een grotere uitgave . De verbouwing van Onno staat me nog vers in het geheugen . Hij werd er om vervloekt door vele forumleden . Een jaar later was GLPG met 500-600% gestegen . Had hij dus gewacht en niet verkocht , dan was de verbouwing 5 maal gratis .
Onno had een jaar later wel 1M geleend toen de koers nog 10-20 euro was voordat de data van de RA trial bekend waren dus het kopen-verkopen zegt wel degelijk wat en ik was bij de koffie bij Onno in najaar 2014 en vond zijn oude huis opknappen wel te begrijpen maar ook niet heel sterk gezien zijn salaris. Ook Tim is qua salaris meer dan verdubbeld sinds de IPO en hoeft ook niet deze 800K te cashen nu. Maar het platform is gewoon echt slim (Hans de Haard is ook een topper en eerder ervaring bij Aby opgedaan) en de recente deal met Abbvie op nieuwe target GARP is een veelbelovende dus blijf rustig zitten.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee